Turn Therapeutics GX-03 Phase 2 interim: 92.6% EASI-50 at 4 weeks; no SAEs

Turn Therapeutics Inc.

92.6% of GX-03 subjects achieved EASI-50 at 4 weeks vs 65.2% vehicle; 70.4% achieved EASI-75.
EASI-90 rates: 44.4% at Week 4 and 51.9% at Week 8 for GX-03 vs 30.4% and 34.8% vehicle.
No treatment-related serious adverse events, tolerability issues, or discontinuations reported.
Enrollment nearing completion; company optimizing trial endpoints and planning FDA meeting.
Detailed data to be presented at Jefferies Global Healthcare conference on June 4, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.